Adenocarcinoma Pancreas
Conditions
Keywords
Adenocarcinoma, imaging, PET, MRI
Brief summary
This study will use PET/MRI in patients with adenocarcinoma of the pancreas to identify hidden metastatic disease or identify patients with borderline or locally advanced disease.
Detailed description
Patients will receive a PET/MRI scan within 6 weeks of their standard of care imaging. There is no maximum number of scans for research. The number of scans depends on each patient's treatment plan.
Interventions
PROCEDUREPET/MRI
PET/MRI
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Presence of suspicious lesion of the pancreas consistent with pancreatic adenocarcinoma. Cytological confirmation is not required. * Patients preparing to receive therapy for pancreas cancer, including patients enrolled in NCT01413022 * Patient must be 18 years or older * Patient must have a life expectancy of more than 6 months and performance status of 2 or less * Patient must be able to understand and willing to sign an approved written informed consent document * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the length of the study * Patients enrolled in the Clinical trials.gov# NCT01413022 trial must meet both studies eligibility criteria.
Exclusion criteria
* Patient must not have had prior resection for pancreatic adenocarcinoma. * Patient must not have a history of other malignancy less than or equal to 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix * Patient must not be unable to receive a PET-MRI scan due to renal function, allergy or other problem with receiving or tolerating an MRI scan, etc. All patients will fill out a standard MRI screening form. * Patients must not have a blood glucose of greater than or equal to 200mg/dL at the time of PET-MRI or if a patient is diabetic and glucose is not controlled. At the discretion of the PI and the authorized user and with their approval prior to 2-\[18\]fluoro-2-deoxy-D-glucose (FDG) injection, patients with blood glucose ≥ 200 mg/dL may participate in the study. * Patient must not be pregnant and/or breast feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PET/MRI compared to conventional CT and MRI | Up to several months or longer. Patient will undergo research imaging with each standard of care scan they have. | Primary outcome is to determine if the primary tumor and the margins of anatomical land marks from the PET/MRI imaging is more precise and gives a clearer picture of tumor location than standard care, CT or MRI. Both standard of care imaging and this new technology will be compared to the final pathologic analysis, measuring the true distance (in mm) between the primary tumor and margins. Data will be reported as mm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Resectability post neoadjuvant treatment | Several months or as deemed a surgical candidate by physician. | The secondary outcome is to determine if PET/MRI imaging is better than standard of care imaging (CT or MRI) after patients have received chemotherapy and to determine if they are surgical candidates. The objective is to determine if the primary tumor and the margins of anatomical land marks from the PET/MRI imaging is more precise and gives a clearer picture of tumor location than standard care, CT or MRI. Both standard of care imaging and this new technology will be compared to the final pathologic analysis, measuring the true distance (in mm) between the primary tumor and margins. Data will be reported as mm. |
Countries
United States
Outcome results
None listed